CSL Vifor Managed Access Programs
In circumstances where patients have exhausted approved treatment options and are not eligible for clinical trials, CSL Vifor supports early access to investigational drugs via Managed Access Programs which describe how healthcare professionals can submit requests for access to investigational drugs on behalf of the patients in their care.
Learn More About These ProgramsSearch Results
176 results found-
CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older.
https://newsroom.csl.com/2023-07-17-CSL-Seqirus-Begins-Shipping-Portfolio-of-Innovative-Influenza-Vaccines-for-the-2023-24-U-S-Season -
A retrospective database analysis of 10 consecutive influenza seasons in Italy found that seasonal influenza placed a significant burden on the pediatric population as measured by pediatrician visits, emergency room visits and hospital admissions, with an average of 8,892 influenza cases among approximately 150,000 children under the age of 14 years each season.
https://newsroom.csl.com/2022-09-26-New-Data-at-OPTIONS-XI-Conference-Highlight-Burden-of-Seasonal-Influenza-on-Health-Systems-and-the-Need-for-Increased-Vaccination-Rates -
LIVING WITH IRON DEFICIENCY SINCE THE AGE OF 16
https://www.csl.com/patients-public-health/iron-deficiency/iron-deficiency-patient-stories/iron-deficiency-andy -
The complex immune system weakens over time and becomes less able to defend the body from infection and illness, but older people can shore it up with healthy habits.
https://www.csl.com/we-are-csl/vita-original-stories/2023/how-the-immune-system-changes-as-you-age -
ST. GALLEN, SWITZERLAND, March 19, 2024 / PRNewswire / -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.
https://newsroom.csl.com/2024-03-19-Ferinject-R-approved-by-Health-Canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure -
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please let us know.
https://www.csl.com/careers/eeo-statement -
CSL is an equal opportunity employer and prohibits discrimination on the basis of gender, nationality, race, ethnicity, disability, sexual orientation, gender identity, age, socioeconomic status, marital/family status, religious beliefs, language, professional and educational background, cultural experiences, and any other criteria protected by applicable law or company policy.
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/diversity-equity-and-inclusion-policy.pdf -
Answers to the most frequently asked questions about Clinical Trials.
https://www.csl.com/research-and-development/clinical-studies/clinical-studies-faqs -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
CIDP can occur at any age and is more common in men than in women.
https://newsroom.csl.com/2024-01-03-CSL-Behring-Announces-Availability-of-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-10g-Prefilled-Syringe